Beatriz Haddad Maia has been provisionally suspended under Article 8.3.1(c) of the 2019 Tennis Anti-Doping Programme (the “Programme”), pending determination of the charge against her at a full hearing pursuant to Article 8 of the Programme. Ms. Haddad Maia, a 23-year-old player from Brazil, provided a urine sample on 4 June 2019 in association with her participation in the WTA Croatia Bol Open held in Bol, Croatia from 3 June to 9 June.

That sample was sent to the World Anti-Doping Agency (“WADA”) accredited laboratory in Montreal, Canada for analysis, and was found to contain SARM S-22 and SARM LGD-4033 metabolite. SARM S-22 and SARM LGD-4033 are Non-Specified substances, which are prohibited under category S1 of the 2019 WADA Prohibited List (Anabolic Agents), and therefore are also prohibited under the Programme. Positive tests for Non-Specified Substances carry a mandatory Provisional Suspension.

On 12 July 2019, Ms. Haddad Maia was charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample) and was Provisionally Suspended with effect from 22 July 2019. Ms. Haddad Maia had (and retains) the right to apply to the Chair of the Independent Tribunal convened to hear her case why the Provisional Suspension should not be imposed, but has chosen not to exercise that right to date.

The Tennis Anti-Doping Programme applies to all players competing at Grand Slam tournaments and events sanctioned by the ITF, ATP, and WTA. Players are tested for substances prohibited by the World Anti-Doping Agency and, upon a finding that an Anti-Doping Rule Violation has been committed, sanctions are imposed under the Programme in compliance with the requirements of the World Anti-Doping Code. More information on the Programme, sanctions, statistics, and related matters can be found at www.itftennis.com/antidoping.

• This media release was published by the International Tennis Federation (ITF) on 23 July 2019. Click here for the original.